AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Hutchmed (China) Limited

Net Asset Value Mar 26, 2018

10503_10-k_2018-03-26_95dffd8a-6eaf-4690-812b-7ff31b258383.html

Net Asset Value

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8420I

Hutchison China Meditech Limited

26 March 2018

2017 Annual Report and

Notice of Annual General Meeting

London: Monday, March 26, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.  The documents can be accessed from the website of Chi-Med (www.chi-med.com).

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1).  For more information, please visit: www.chi-med.com.

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President, Corporate

Finance & Development
+852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) [email protected]
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) [email protected]
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) [email protected]
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) [email protected]
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) [email protected]
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSPGUQAWUPRPUA

Talk to a Data Expert

Have a question? We'll get back to you promptly.